Question for the board: From the PR today, it sounds like they are going to separate GNBT from the Nugenerex and create a new publicly traded stock. "The spin-out of NuGenerex Immuno-Oncology into a separate, publicly traded entity has been the focus of the Generex strategic development plan in cancer drug development," Mr. Moscato indicated. So how does this affect GNBT?